Welcome to Drug and Therapeutics Bulletin (DTB)
For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals.
DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship.
Andrew Herxheimer (1925-2016)
It is with great sadness that we report that Andrew Herxheimer, founding editor of DTB, has died. Andrew set up the Bulletin in 1962 to provide rigorous, independent and unbiased evaluations of drugs and other therapeutic interventions. He continued to edit it for over 30 years and, under his leadership, DTB became a well-respected and influential publication committed to the provision of clear, concise and practical information on the use of medicines. We offer our condolences to Andrew’s family.
Read the full obituary >>
Upcoming DTB topics include:
Oxycodone/naloxone for restless legs syndrome
Religious and cultural beliefs and medicines
Midodrine for orthostatic hypotension
Guanfacine for ADHD
Sacubitril/valsartan for heart failure
Polypharmacy and Empagliflozin reviewed
Read educational articles published in DTB and then test your knowledge on BMJ Learning: